{"id":545896,"date":"2021-06-02T19:16:02","date_gmt":"2021-06-02T19:16:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=545896"},"modified":"2021-06-02T19:16:02","modified_gmt":"2021-06-02T19:16:02","slug":"cardiotoxicity-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cardiotoxicity-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_545896.html","title":{"rendered":"Cardiotoxicity Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Cardiotoxicity<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cCardiotoxicity\u2013Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Cardiotoxicity, historical and forecasted epidemiology as well as the Cardiotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight has launched a new report on “Cardiotoxicity-Market Insights, Epidemiology, and Market Forecast-2030”.<\/strong><\/p>\n

DelveInsight’s<\/span> “Cardiotoxicity–Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/span>” report delivers an in-depth understanding of the Cardiotoxicity, historical and forecasted epidemiology as well as the Cardiotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n

Some of the key facts of the Report:<\/span><\/strong><\/p>\n

1. According to the report, late-onset chronic progressive anthracycline-induced cardiotoxicity occurs at least 1 year after completing therapy in 1.6−5% of patients though it may not become clinically evident until 10–20 years after the first dose of therapy.<\/p>\n

2. In a study, cardiotoxicity was observed in 39.6% of patients receiving anthracycline. It was also observed in the patients receiving the following medications: Anti HER2 (43.5%), anthracycline and anti-HER2 (45.7%), TKI (50%), left breast radiotherapy (44.8%), and mediastinal radiotherapy (29.1%) (Sendon et al., 2020).<\/p>\n

3. A researcher stated that immune checkpoint inhibitors (antitumor agents) ipilimumab and nivolumab lead to a range of immune-related toxicities, including myocarditis and the incidence of myocarditis in patients taking these agents was between 0.27% and 1.14%.<\/p>\n

Key benefits of the report:<\/strong><\/p>\n

1.The Cardiotoxicity market report covers a descriptive overview and comprehensive insight of the Cardiotoxicity epidemiology and Cardiotoxicity market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span><\/p>\n

2.The Cardiotoxicity market report provides insights into the current and emerging therapies.<\/span><\/p>\n

3.Cardiotoxicity market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/span><\/p>\n

4.The Cardiotoxicity market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cardiotoxicity market.<\/span><\/p>\n

Request for sample pages<\/span>: https:\/\/www.delveinsight.com\/sample-request\/cardiotoxicity-market<\/span><\/a><\/span>
<\/span><\/a><\/strong><\/p>\n

Cardiotoxicity: Overview<\/span><\/strong><\/p>\n

Cardiotoxicity is a condition when there is damage to the heart muscle. It may be caused by chemotherapy drugs or medications concerning other diseases. As a result of cardiotoxicity, the heart becomes weaker and is unable to pump blood throughout the body. <\/span><\/p>\n

Several cancer drugs and treatments can cause direct damage to the heart. These drugs can cause many cardiac issues, including heart failure, high blood pressure, low blood pressure, heart attacks, irregular heartbeat, slow heart rate, or fluid around the heart.<\/p>\n

The key players involved in the Cardiotoxicity market:<\/a><\/strong><\/p>\n

 <\/p>\n

    \n
  1. \n

    Moleculin Biotech<\/span><\/p>\n<\/li>\n

  2. \n

    Monopar Therapeutics<\/span><\/p>\n<\/li>\n<\/ol>\n

    The launch of the emerging therapies is expected to significantly impact the  Cardiotoxicity treatment scenario in the upcoming years:-<\/strong><\/p>\n

    Drug covered<\/span><\/strong><\/p>\n

      \n
    1. \n

      Annamycin<\/span><\/p>\n<\/li>\n

    2. \n

      Camsirubicin<\/span><\/p>\n<\/li>\n<\/ol>\n

      Request a free sample report @ https:\/\/www.delveinsight.com\/sample-request\/cardiotoxicity-market<\/span><\/a><\/strong><\/p>\n

      Table of Contents<\/span><\/strong><\/p>\n

      1. Report Introduction<\/span><\/p>\n

      2. Executive Summary<\/span><\/p>\n

      3. SWOT analysis<\/span><\/p>\n

      4. Cardiotoxicity Patient Share (%) Overview at a Glance<\/span><\/p>\n

      5. Cardiotoxicity Market Overview at a Glance<\/span><\/p>\n

      6. Cardiotoxicity Disease Background and Overview<\/span><\/p>\n

      7. Cardiotoxicity Epidemiology and Patient Population<\/span><\/p>\n

      8. Country-Specific Patient Population of Cardiotoxicity <\/span><\/p>\n

      9. Cardiotoxicity Current Treatment and Medical Practices<\/span><\/p>\n

      10. Unmet Needs<\/span><\/p>\n

      11. Cardiotoxicity Emerging Therapies<\/span><\/p>\n

      12. Cardiotoxicity Market Outlook<\/span><\/p>\n

      13. Country-Wise Cardiotoxicity Market Analysis (2017–2030)<\/span><\/p>\n

      14. Market Access and Reimbursement of Therapies<\/span><\/p>\n

      15. Market drivers<\/span><\/p>\n

      16. Market barriers<\/span><\/p>\n

      17. Appendix<\/span><\/p>\n

      18. Cardiotoxicity Report Methodology<\/span><\/p>\n

      19. DelveInsight Capabilities<\/span><\/p>\n

      20. Disclaimer<\/span><\/p>\n

      21. About DelveInsight<\/span><\/p>\n

      Related Reports:<\/strong><\/p>\n

      Cardiotoxicity-Pipeline Insights, 2021<\/span><\/strong><\/p>\n

      “<\/span>Cardiotoxicity-Pipeline Insight, 2021<\/span>” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cardiotoxicity market. A detailed picture of the Cardiotoxicity pipeline landscape is provided, which includes the disease overview and Cardiotoxicity treatment guidelines.<\/span><\/p>\n

      Cardiotoxicity-Epidemiology Forecast to 2030<\/span><\/strong><\/p>\n

      DelveInsight’s <\/span>‘Cardiotoxicity-Epidemiology Forecast to 2030’ <\/span>report delivers an in-depth understanding of the disease, historical and forecasted Cardiotoxicity {;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/span><\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Kritika Rehani
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> 9193216187
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Las Vegas
      State:<\/strong> Nevada
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      DelveInsight Business Research LLP DelveInsight\u2019s \u201cCardiotoxicity\u2013Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Cardiotoxicity, historical and forecasted epidemiology as well as the Cardiotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-545896","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=545896"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545896\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=545896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=545896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=545896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}